Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
复制标题
DOI：
10.1016/0264-410x(95)00186-5
复制
发表时间：
1996-04-01
期刊：
影响因子：
5.5
通讯作者：
LeCam, NN
中科院分区：
文献类型：
--
作者：
Klugman, KP;Koornhof, HJ;LeCam, NN
采用随机双盲试验方法，观察伤寒Vi衣壳多糖疫苗接种3年后的保护力和免疫原性。在一项病例对照研究中，在接种后3年的病例对照研究中，用放射免疫测定法和被动血凝试验测得的Vi抗体水平分别为1.28vs0.76mgml(-1，P=0.0004)和3.52vs3.52(P=0.0001)。使用两组伤寒的相对风险和抗体水平的相对比率来评估保护的血清学相关性。估计的保护水平为1微克毫升(-1)，提示在平均9岁时，%的疫苗接种者和40%的对照人员对伤寒具有保护性抗体。版权所有(C)1996爱思唯尔科学有限公司。
The protective efficacy and immunogenicity of Vi capsular polysaccharide vaccine against typhoid fever was measured 3 years after its administration in a double-blind randomized trial. Vaccine efficacy was not significantly different during each year of the trial and was 55% (95% CI: 30-71%) over the 3 year period In a case-control study at 3 years after vaccination, recipients of Vi had higher levels of Vi antibodies than controls, as measured by radio-immunoassay (GMT 1.28 vs 0.76 mu g ml(-1), P=0.0004) and by passive haemagglutination assay (GMT 10.46 vs 3.52, P=0.0001). The serological correlate of protection has been estimated using the relative risks of typhoid fever in the 2 groups and the relative ratio of antibody levels. The estimated protective level is I mu g ml(-1) suggesting that at a mean age of 9 years, 64% of vaccinates and 40% of controls had protective antibody against typhoid fever in this endemic area. Copyright (C) 1996 Elsevier Science Ltd.